Genentech Inc. is licensing a human monoclonal antibody for autoimmune diseases.
Financial terms and other aspects of the deal between the South San Francisco-based unit of Swiss drug maker Roche and NovImmune of Switzerland were not disclosed.
Genentech will get access to an anti-IL-17 fully humanized monoclonal antibody and backup antibodies, the companies said. The antibody is in late-stage development by NovImmune researchers, the company said....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397